A growing body of data demonstrates that NADPH:quinone oxidoreductase 1 (NQO1), a phase II two-electron reductase that can bioactivate certain quinone molecules and shows a protective effect against natural and exogenous quinones, is abnormally upregulated in many solid cancers, such as lung, pancreatic, breast, prostate, and colon cancers (4–11). Here, NQO1 is linked to malignant colon neoplasm.